> 75 years showed significantly lower progression-free (PFS) and overall survival in multivariate analysis. A CEA response of > 30% during treatment was associated with increased PFS. In addition, the pattern of CEA kinetics predicts survival and response to treatment. Conclusion: In summary, baseline CEA, number of metastatic sites, and age are strong independent prognostic factors for survival. By monitoring CEA, clear patterns with distinct prognostic value can be determined. CEA kinetics and/or response after 8-12 weeks might be a useful and simple tool to stratify the post-induction treatment approach based on individual prognosis in the future.
Introduction
Colorectal cancer (CRC) is among the most frequently diagnosed cancers in Europe and one of the leading causes of cancer death worldwide [1, 2] . Around one quarter of patients with CRC present with metastatic disease (mCRC) at the time of diagnosis Keywords Metastatic colorectal cancer · Bevacizumab · Baseline prognostic factors · Carcinoembryonic antigen · Kinetics Summary Background: In metastatic colorectal cancer, no upfront or on-treatment markers are available to determine the prognosis or efficacy for chemotherapy in combination with bevacizumab. Patients and Methods: The current analysis was performed to evaluate the prognostic value of disease and patient characteristics (age, number of metastatic sites, stage of primary tumor, performance status, carcinoembryonic antigen (CEA)) and on-treatment changes of CEA (response after 8-12 weeks of treatment and specific patterns of CEA kinetics) in patients from an observational cohort study of chemotherapy with bevacizumab. Results: Baseline factors were available from 1,438 patients. Patients with baseline CEA levels > 20 ng/ml, more than 1 metastatic site, and age (synchronous disease), and up to 40% of patients will develop metastases during the course of their disease, resulting in a high overall mortality rate [3] .
Several drugs as single agents or in various combinations are available in metastatic CRC (mCRC), including fluoropyrimidines (5-fluorouracil (5-FU), capecitabine), irinotecan, oxaliplatin, trifluridine/tipiracil, the vascular endothelial growth factor (VEGF) antibody bevacizumab, the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab for RAS wildtype patients, the VEGF receptor 1 and 2 fusion protein aflibercept, and the multitarget tyrosine kinase inhibitor regorafenib. The standard firstline treatment is a combination of a chemotherapy doublet of a fluoropyrimidine with oxaliplatin and/or irinotecan (FOLFOX, CAPOX, FOLFIRI regimen) with bevacizumab or an EGFR antibody (cetuximab or panitumumab). Based on recent advances in treatment development, median overall survival (OS) can now be as long as 30 months in selected patient groups [4] [5] [6] [7] . However, despite these dramatic improvements, it remains a challenge to determine individual prognosis and treatment efficacy.
During the last decade, certain molecular markers have been identified which have enabled a tailored treatment approach, e.g. mutations in the KRAS and NRAS genes which negatively impact the efficacy of EGFR antibodies [8] .
Furthermore, several on-treatment markers have been described which confer resistance to EGFR antibodies [9] [10] [11] . For anti-angiogenic agents, particularly for bevacizumab, no baseline predictive molecular markers are established. Although changes in angiogenic factors (e.g. PlGF) in the serum may indicate future progression, these factors are difficult to measure and highly variable [12] .
A variety of clinical prognostic factors have been evaluated and combined in scores in the treatment of mCRC, showing the high relevance of performance status, number of metastatic sites, age, and tumor stage [13] [14] [15] . In addition, elevated serum carcinoembryonic antigen (CEA) is a poor prognostic factor for both localized and metastatic disease [16] [17] [18] .
The current analysis was conducted to explore both, the prognostic information to be derived from baseline disease and patient characteristics (age, number of metastatic sites, stage of primary tumor, performance status, CEA) as well as the utility of the easy to measure on-treatment marker CEA in a large cohort of mCRC patients treated with first-line chemotherapy and bevacizumab.
Patients and Methods
The reported data were obtained in patients with histologically confirmed mCRC within a large community-based observational cohort study of various chemotherapy regimens in combination with bevacizumab in Germany (1,777 eligible patients, recruited between 2005 and 2008). Efficacy and safety results of this non-interventional study have been reported elsewhere [19] .
The current analysis included all patients with available baseline clinical factors and CEA levels and information on tumor response, progression-free survival (PFS), and overall survival (OS) (n = 1,438). Patients underwent protocoldefined radiographic assessment (computed tomography or magnetic resonance imaging) according to RECIST version 1.0 every 8-12 weeks [20] .
Patient data were analyzed for correlations between baseline parameters (age, number of metastatic sites, stage of primary tumor, performance status, CEA /> 20 ng/ml) and overall clinical efficacy in terms of PFS and OS. In addition, changes in CEA during treatment were correlated with efficacy using different categories. At first, a CEA response within 8-12 weeks of treatment defined according to RECIST criteria (> 30% decrease compared to baseline) was correlated with clinical efficacy in patients with elevated baseline CEA (> 5 ng/ml) and available follow-up data. Secondly, CEA kinetics during treatment were analyzed according to previously defined criteria [21] . In the case of elevated CEA at baseline (> 5 ng/ml), patterns were defined as flare ( 15% rise from baseline, defined as a minimum of 4 ng/ml, followed by a subsequent 15% decrease from baseline), decrease and increase (> 10% compared to baseline), or stable (+/-10% compared to baseline).
Statistical Considerations
PFS was defined as the period from the start of first-line chemotherapy until disease progression, death, or being censored at the last follow-up. OS was defined as the period from the start of first-line chemotherapy until death from any cause or being censored at the last follow-up. These event-related data were estimated according to the Kaplan-Meier method and compared between prognostic groups using the log-rank test. For multivariate analysis, the Cox proportional hazards model was applied, including all univariately significant parameters and implementing a stepwise backward procedure for variable selection. All p values are two-sided and of exploratory nature.
Results

Patient and Disease Characteristics
The patient population of the observational cohort comprised 1,777 patients. Overall 1,438 patients with available baseline pa- rameters were included in the current analysis (overall population). For CEA response within 8-12 weeks 474 patients were evaluable, and for CEA kinetics within a 6-month period 1,070 patients. Baseline characteristics of the overall population are summarized in table 1. Median age was 64.5 years (range 19-100 years). An ECOG performance status of 0 or 1 was found in 88% of patients. The majority of patients had synchronous metastatic disease (57%). In the overall patient cohort, 70% of patients had only 1 metastatic site and 75% had liver metastases.
Treatment
In the overall cohort (n = 1,777), a median number of 8 cycles (range 1-24 cycles) of bevacizumab with or without chemotherapy with a median treatment duration of 7 months (range 0-37 months) was administered. The initial chemotherapy was irinotecan-based (68%, n = 1,200), oxaliplatin-based (19%, n = 335), or single agent fluoropyrimidine (12%, n = 209; with 5-FU in 9% of cases). Single-agent bevacizumab was administered in 2% (n = 36) of patients. In 8%, capecitabine was applied either as a single agent or combined with oxaliplatin (3%, n = 57) or irinotecan (2%, n = 34).
Efficacy
Among the overall population (n = 1,438), a complete or partial response was seen in 61% (n = 877), stable disease in 29% (n = 390), and progressive disease in 7% (n = 98) of patients as best response, according to the treating physician's assessment. 5% of patients were not evaluable for response. Median PFS was 10.1 months (95% confidence interval (CI) 9.5-10.6), and median OS was 24.8 months (95% CI 23.7-26.3).
Baseline Prognostic Parameters for First-Line Chemotherapy in Combination with Bevacizumab
In univariate analysis (table 2), the main prognostic factors for PFS and OS were CEA baseline value and age, followed by number of metastatic sites and performance status. In multivariate analysis 
Efficacy According to CEA Response within 8-12 Weeks
Patients with CEA response (n = 205), defined as at least 30% decrease within 8-12 weeks of treatment, showed a significantly better PFS (median 11.27 vs. 8.77 months, p = 0.0078) compared to non-responders (n = 269) ( fig. 1) . No difference in OS (median 23.9 vs. 22.7 months, p = 0.38) could be demonstrated.
Pattern of CEA Kinetics
Overall, 1,070 patients were eligible for analysis of CEA kinetics, with 4% (n = 38) showing flare phenomenon, 19% (n = 207) increase, 54% (n = 578) decrease, and 5% (n = 52) stable CEA, whereas 18% (n = 195) had a normal baseline value. Sex, age, ECOG performance status, leukocytes at baseline, oxaliplatin-or irinotecan-based chemotherapy, and location of metastatic disease were equally distributed between the groups.
Interestingly, the rate of synchronous metastatic tumors was highest in the flare group (81%) and lowest in the normal baseline group (50%) compared to 57% in the overall population. TNM stage and grading showed a trend towards higher stage (T4 or N2) and worse grading (G3) in the flare group. Baseline CEA in the flare group was 4 times higher (median 107.5 ng/ml) than in the overall population (26.5 ng/ml). The vast majority of patients with normal baseline CEA had only a single metastatic site (78%) and a comparably low rate of liver involvement (52 vs. 72%).
Efficacy data according to patterns of CEA kinetics are displayed in table 4. PFS ( fig. 2 ) and OS significantly differed between patient groups with different CEA kinetics. Patients with CEA increase had the worst outcome (median OS 18.2 months), whereas patients with normal CEA at baseline had the best prognosis (median OS of 34.2 months), even better than patients with CEA decrease (median OS of 25.1 months). Of note, patients with CEA increase, albeit having the lowest overall response rate, still responded to first-line treatment in combination with bevacizumab (complete or partial response in 47% of patients compared to 65% in the overall CEA kinetics group) (table 4).
Discussion
The reported cohort reflects a standard first-line mCRC population in terms of patient and disease characteristics. The rate of irinotecan-based combination treatment is higher as previously reported in other observational and database analyses [22] [23] [24] [25] . This is likely related to the study recruitment period from 2005 to 2008 before the combination of oxaliplatin and bevacizumab was licensed in Europe. The survival data with a median PFS of 10.1 months and OS of 24.8 months are within the expected range of a first-line regimen with bevacizumab [19, [26] [27] [28] . The overall response rate of 61% seems to be relatively high, which might be explained by the investigator-assessed response without centralized review.
The baseline poor prognostic factors for first-line chemotherapy in combination with bevacizumab are CEA (cut-off 20 ng/ml), age (cut-off 75 years), and number of metastatic sites (cut-off n = 1) in multivariate analysis. In addition, for PFS, ECOG performance status (> 1) and for OS, TNM stage (T4 or node positivity) were independent poor prognostic factors. Previously reported for age, ECOG performance status, and number of metastatic sites, the current analysis shows for the first time the high prognostic impact of baseline CEA even in a multivariate model. Thus, CEA should be included in future prognostic models or as a stratification factor.
Within the observational study, data on molecular markers and sidedness were not available for analysis. Future models should clearly include these factors in addition to patient factors and CEA.
Of note, besides its baseline prognostic value, CEA might be a useful tool for monitoring the course of disease during treatment. In the metastatic setting, current standard evaluation of disease status is via computed tomography or magnetic resonance imaging, applying the response evaluation criteria in solid tumors (RECIST) [29] . Monitoring of CEA is a highly standardized and low-cost supplemental method. Although treatment decisions should be based on radiographically documented response status, this simple and easy to measure serum marker might give timely information about current disease status and, beyond that, trigger early imaging e.g. in the case of suspected progression [30] [31] [32] . However, about 20-25% of patients do not present with elevated CEA levels at baseline, with the majority remaining normal during the course of their disease.
CEA response (decrease by 30% compared to baseline) within the first 8-12 weeks significantly predicts favorable PFS, whereas there is no impact on OS. Therefore, CEA response yields prognostic information in the course of first-line chemotherapy and bevacizumab, potentially useful for the stratification of patients for further treatment, e.g. maintenance after induction chemotherapy, and may be further evaluated in randomized trials. Compared to other prognostic factors (e.g. molecular markers or profiles or radiographic parameters like early tumor shrinkage), monitoring of CEA offers a simple, reliable, and inexpensive method to get individual prognostic information for mCRC patients. Notably, CEA response does not predict favorable OS, which besides a selection bias may in part be explained by the preselection of a patient group with an already poor prognosis. The survival of mCRC patients with baseline elevated CEA > 20 ng/ml is significantly decreased (table 3), whereas patients with normal CEA baseline values (< 5 ng/ml) will achieve the best survival (table 4) .
Further analyses were performed regarding CEA kinetics during treatment. The current data confirm the distribution and differential clinical efficacy between the different patterns of CEA kinetics, as previously shown [21] . However, this is the largest report to date of CEA kinetics in patients undergoing first-line treatment with an anti-angiogenic drug. Interestingly, CEA flare patients, despite showing worse survival than CEA decrease patients, end up with a survival similar to patients with stable CEA values. Accordingly, initial CEA increases should be followed up to identify CEA flare patients. The very good prognosis of patients with normal CEA baseline values (OS of about 35 months) underlines the strong prognostic value of baseline CEA. Tumors in patients with normal baseline CEA seem to yield a less aggressive biology with a high rate of metachronous metastases, low rate of liver metastases, and involvement of only 1 site (78%). In contrast, the flare group showed less favorable tumor features with a high rate of synchronous and less differentiated (grade 3) tumors. Thus, CEA kinetics clearly reflect the tumor biology and might give additional prognostic or treatment information besides the mentioned baseline factors. Overall, baseline CEA and (at least for the course of firstline treatment) CEA response (30% decrease) after 8-12 weeks are relevant prognostic factors and may be included in models (e.g. stratification in clinical trials or for treatment approaches).
Conclusion
CEA baseline value, age, and number of metastatic sites are strong and independent prognostic factors of survival in patients receiving first-line chemotherapy combined with bevacizumab for mCRC. In addition to imaging, monitoring of initially elevated CEA after 8-12 weeks allows simple and low-cost disease assessment which might be useful for individualizing treatment in the future.
